Urotensin II receptor expression in human right atrium and aorta: Effects of ischaemic heart disease

British Journal of Anaesthesia

Volumn 102, Issue 4, 2009, Pages 477-484

  Leonard, A D ^a   Thompson, J P ^a   Hutchinson, E L ^a   Young, S P ^a   McDonald, J ^a   Swanevelder, J ^b   Lambert, D G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Heart, cardiopulmonary bypass; Heart, failure; Heart, myocardial function; Model, G protein coupled receptor; Monitoring, echocardiography; Polymerase chain reaction; Urotensins

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; RNA; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ADULT; AGED; AORTA; ARTICLE; BLOOD VESSEL BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART RIGHT ATRIUM; HEART VENTRICULOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOIMMUNOASSAY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 62549148144     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep011     Document Type: Article

References (34)

1. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25: 76-85
2. Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006; 148: 884-901
3. McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth 2007; 21: 378-89
4. Gardiner SM, March JE, Kemp PA, et al. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 2006; 147: 612-21
5. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001; 132: 1625-9
6. Behm DJ, Harrison SM, Ao Z, et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003; 139: 464-72
7. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004; 109: 1212-4
8. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005; 18: 1195-9
9. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002; 53: 341-7
10. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002; 54: 617-21
11. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106: 2877-80
12. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990-7
13. Barnes TA, McDonald J, Rowbotham DJ, Duarte TL, Lambert DG. Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 217-25
14. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006; 28: 1601-13
15. Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 2003; 97: 1501-3
16. Gold SJ, Thompson JP, Williams JP, et al. Does cigarette smoking increase plasma urotensin II concentrations? Eur J Clin Pharmacol 2007; 63: 253-7
17. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810-1
18. Zhong P, Li ZL, Wu HC, Tang CS, Lu Q. Clinical study of changes of urotensin II in patients with congestive heart failure. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 121-3
19. Kruger S, Graf J, Kunz D, et al. Urotensin II in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 475-8
20. Dschietzig T, Bartsch C, Pregla R, et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 2002; 110: 33-8
21. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004; 94: 93-7
22. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006; 27: 1527-31
23. Sidharta PN, Wagner FD, Bohnemeier H, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006; 80: 246-56
24. Cosenzi A. Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovasc Hematol Agents Med Chem 2008; 6: 80-91
25. Nakayama T, Hirose T, Totsune K, et al. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides 2008; 29: 801-8
26. Pirracchio R, Cholley B, De Hert S, Cohen Solal A, Mebazaa A. Diastolic heart failure in anaesthesia and critical care. Br J Anaesth 2007; 98: 707-21
27. Ten Brinke EA, Klautz RJ, Tulner SA, et al. Haemodynamics and left ventricular function in heart failure patients: comparison of awake versus intra-operative conditions. Eur J Heart Fail 2008; 10: 467-74
28. Reuter DA, Goresch T, Goepfert MS, Wildhirt SM, Kilger E, Goetz AE. Effects of mid-line thoracotomy on the interaction between mechanical ventilation and cardiac filling during cardiac surgery. Br J Anaesth 2004; 92: 808-13
29. Kidd JE, Gilchrist NL, Utley J, Nicholls MG, Espiner EA, Yandle TG. Effect of opiate, general anaesthesia and surgery on plasma atrial natriuretic peptide levels in man. Clin Exp Pharmacol Physiol 1987; 14: 755-60
30. A receptor activation on UT-coupled signalling pathways in rat cortical astrocytes. Peptides 2008; 29: 727-34
31. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-61
32. Kamkin A, Kiseleva I, Wagner KD, et al. Mechano-electric feedback in right atrium after left ventricular infarction in rats. J Mol Cell Cardiol 2000; 32: 465-77
33. Kamkin A, Kiseleva I, Wagner KD, et al. A possible role for atrial fibroblasts in post infarction bradycardia. Am J Physiol Heart Circ Physiol 2002; 282: H842-9
34. Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003; 108: 1461-8